Meeting
2019 ASCO Annual Meeting
Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.
Authors
Mark Rosenthal
Peter MacCallum Cancer Centre, Melbourne, Australia
Mark Rosenthal , Carmen Balana , Myra Ellen Van Linde , Cyrus Sayehli , Walter M. Fiedler , Martin Wermke , Christophe Massard , Agnes Ang , Johannes Kast , Sabine Stienen , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03296696
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2071)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2071
Abstract #
TPS2071
Poster Bd #
260a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).
First Author: Behnam Badie
Poster
2014 ASCO Annual Meeting
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.
First Author: Juan Manuel Sepúlveda
Poster
2023 ASCO Annual Meeting
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
First Author: Mason Webb
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca